Product image of Letrohexal (Letrozole) supplied by GNH India

Letrohexal

Active Ingredient:
Letrozole
Origin:
EU

Letrohexal (Letrozole)

Letrozole, the active ingredient in Letrohexal, is an aromatase inhibitor presented as an oral tablet for systemic use. It is employed in the treatment of hormone receptor‑positive breast cancer in postmenopausal women, both as adjuvant therapy and for advanced disease management.

GNH India supplies Letrohexal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for global oncology treatment programs, including temperature‑controlled logistics where required.

Manufacturer / TM Owner

Hexal Ag

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Letrohexal, an aromatase inhibitor, is indicated for estrogen‑driven breast cancer conditions.
  • Hormone receptor‑positive breast cancer (postmenopausal): Reduces estrogen levels to inhibit tumor growth.
  • Adjuvant treatment of early‑stage breast cancer (postmenopausal): Decreases risk of recurrence after surgery.
  • Metastatic breast cancer (postmenopausal): Provides disease control in advanced settings.

How It Works

  • Letrozole selectively binds to the aromatase enzyme, blocking the conversion of adrenal and peripheral androgens into estrogens. By lowering circulating estrogen concentrations, it diminishes estrogen‑mediated stimulation of hormone‑sensitive breast cancer cells, thereby slowing tumor proliferation and progression.

Side Effects

Letrohexal may cause a range of adverse reactions. Patients should be monitored for any new or worsening symptoms.

Common Side Effects

  • Hot flashes: Sudden feeling of warmth and sweating.
  • Joint and muscle pain: Arthralgia or myalgia affecting daily activities.
  • Fatigue: Persistent tiredness not relieved by rest.
  • Nausea: Mild to moderate upset stomach.
  • Headache: Tension‑type or throbbing pain.
  • Dizziness: Light‑headed sensation, especially when standing.

Serious or Rare Side Effects

  • Severe liver injury: Jaundice, dark urine, or elevated liver enzymes.
  • Pulmonary embolism: Sudden shortness of breath, chest pain, or coughing up blood.
  • Bone fracture: Increased risk of osteoporosis‑related fractures.
  • Allergic reactions: Rash, itching, swelling, or anaphylaxis.
  • QT interval prolongation: Potential cardiac arrhythmias.

Precautions & Warnings

  • Before initiating Letrohexal, clinicians should evaluate patient history and monitor specific parameters.
  • Pregnancy avoidance: Contraindicated in pregnancy (Category X) due to teratogenic risk.
  • Breastfeeding: Not recommended; letrozole may pass into breast milk.
  • Bone health monitoring: Assess bone mineral density regularly and consider calcium/vitamin D supplementation.
  • Cardiovascular risk: Monitor blood pressure and signs of thromboembolic events.
  • Drug interactions: Review concomitant medications for CYP2A6 or CYP2C19 inhibitors.
  • Store at ambient temperature: Keep below 25 °C, protect from moisture and light in the original container.

Avoid Interactions

Letrohexal can interact with several medicines; careful review is essential.

Major Interactions (Avoid)

  • Strong CYP2A6 inhibitors (e.g., ketoconazole): May increase letrozole plasma concentrations.
  • Concurrent tamoxifen therapy: Antagonistic effect on estrogen suppression.
  • Warfarin: Potentially heightened anticoagulant effect leading to bleeding.

Moderate Interactions (Monitor Closely)

  • CYP2C19 inhibitors (e.g., fluoxetine): May modestly raise letrozole levels.
  • Antacids containing aluminum or magnesium: May reduce oral absorption of letrozole.
  • Selective serotonin reuptake inhibitors (SSRIs): May influence bone metabolism and fracture risk.

Frequently Asked Questions

Letrohexal contains letrozole, an aromatase inhibitor indicated for the treatment of hormone receptor‑positive breast cancer in postmenopausal women. It is used both as adjuvant therapy after surgery and as a systemic option for advanced or metastatic disease.

Letrozole blocks the aromatase enzyme, which converts androgens into estrogens in peripheral tissues. By suppressing estrogen production, it lowers circulating estrogen levels, reducing the hormonal stimulus that drives growth of estrogen‑dependent breast cancer cells.

The prescribed dose of Letrohexal is determined by the treating physician based on the patient’s clinical condition, disease stage, and individual tolerance. Healthcare professionals follow established oncology guidelines when selecting the appropriate regimen.

Letrohexal is classified as pregnancy category X, meaning it is contraindicated during pregnancy due to known fetal risk. It is also not recommended for breastfeeding women because letrozole can be excreted in breast milk and may affect the infant.

To request Letrohexal, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Letrohexal (letrozole) is a non‑steroidal aromatase inhibitor with a high potency and a longer half‑life compared with anastrozole, another non‑steroidal agent. Exemestane, a steroidal inhibitor, binds irreversibly to aromatase. Clinical choice depends on efficacy, tolerability, patient comorbidities and physician preference.

Letrohexal tablets should be stored at ambient temperature, preferably below 25 °C, in their original blister pack to protect from moisture and light. Keep the product out of reach of children and avoid storing in bathrooms or other humid environments.

Letrohexal is taken orally, usually once daily, with or without food. Patients should swallow the tablet whole with water and follow the dosing schedule prescribed by their oncologist. Consistency in timing helps maintain stable drug levels.

Serious risks include severe liver injury, pulmonary embolism, osteoporosis‑related fractures, and rare cardiac arrhythmias such as QT prolongation. Patients should be monitored regularly for liver function, signs of thromboembolism, bone health, and any cardiac symptoms.

Letrohexal is contraindicated in premenopausal women, pregnant or lactating individuals, and patients with known hypersensitivity to letrozole or any tablet excipients. Caution is also advised for patients with severe hepatic impairment or uncontrolled cardiovascular disease.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Letrozole

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT